Drugs Used in the Treatment of Multiple Sclerosis

Core Concepts

Goal 1: Treating acute relapses with corticosteroids

An MS relapse is a burst of CNS inflammation. High-dose corticosteroids (e.g., intravenous methylprednisolone) are the mainstay of acute relapse treatment: they reduce inflammation and shorten the episode. They do not prevent future relapses or slow long-term disability — that is the DMTs’ job. Short-course side effects include insomnia, mood changes, glucose elevation, and GI upset.

Goal 2: Disease-modifying therapies (DMTs)

DMTs are the backbone of long-term MS care; choice depends on disease course, activity, prior treatments, monitoring capacity, and patient preference — a shared decision with the care team.

Immunomodulators: interferons and glatiramer acetate

Interferon beta, an injected cytokine, modulates the immune response toward less inflammatory activity, reducing relapse rates. Glatiramer acetate is a synthetic myelin-like polymer that promotes regulatory, anti-inflammatory immune responses rather than the attack. Both are self-injected; injection-site reactions and flu-like symptoms (especially interferons) are common teaching points.

Lymphocyte-trafficking modulators: S1P receptor modulators

Drugs such as fingolimod (and related agents) bind S1P receptors on lymphocytes, trapping them in lymph nodes so fewer reach the CNS — fewer attacks. Key teaching points: first-dose cardiac monitoring, blood-count monitoring, infection risk, and, for some agents, eye checks. These are oral agents many people prefer over injections — but “easier to take” does not mean “lighter” drug; monitoring is mandatory.

Monoclonal antibodies: targeted immune-cell weapons

Monoclonal antibodies bind specific immune-cell targets:

• Natalizumab blocks an adhesion molecule (α4-integrin/VLA-4), preventing immune cells from crossing the blood–brain barrier; highly effective, it carries a rare, serious risk of PML, a JC-virus brain infection — screening and risk stratification are part of its use.
• Alemtuzumab depletes lymphocytes (targeting CD52); highly effective, it brings infusion reactions and later secondary autoimmune problems (e.g., thyroid disease) needing long-term surveillance.
• Ocrelizumab targets CD20 on B cells, depleting them; used for relapsing MS and, in some regions, primary progressive MS, with infusion and infection risks among the main concerns.

These are powerful drugs with heavy monitoring commitments; specifics come from current references and the prescriber.

Other DMT mechanisms

Other agents work differently: teriflunomide limits immune-cell proliferation by inhibiting pyrimidine synthesis (and is teratogenic), dimethyl fumarate reduces inflammation and oxidative stress, mitoxantrone is an older immunosuppressant with cardiotoxicity and leukemia risk (used rarely), and cladribine depletes lymphocytes in short courses.

Symptom management and rehabilitation

Beyond DMTs, care addresses spasticity, neuropathic pain, bladder dysfunction, fatigue, and depression with targeted drugs plus physical, occupational, and speech therapy; heat sensitivity is managed with cooling.

Nursing implications

• Know which goal each drug serves: steroids for the relapse; DMTs for the long game.
• Teach the schedule and technique for injections, infusions, or oral agents.
• Infection vigilance: fever or new symptoms on an immune-altering drug are reported.
• Pregnancy planning: several DMTs have significant reproductive precautions; discuss before conception.
• Live vaccines are avoided or carefully timed on many therapies.
• Scope note: administration, teaching, and monitoring are nursing responsibilities; regimen and risk decisions follow prescriber orders and institutional policy.

Common Confusions